We published our ideas and vision on Advancing RNA with Michael Solaway.

Link to article: https://www.advancingrna.com/doc/rna-s-evolutionary-logic-is-quietly-rewriting-the-future-of-therapeutics-a-conversation-with-ahmet-berkyurek-0001

Ahmet Berkyurek, CEO of CamMed Therapeutics Ltd., argues that the future of RNA therapeutics lies in working with — not against — RNA’s natural evolutionary design. Rather than treating biological constraints like instability as problems, researchers are beginning to see them as essential design principles shaped by billions of years of evolution.

Berkyurek highlights RNA’s unique properties — adaptability, responsiveness, and controlled degradation — as key advantages for developing precise and dynamic therapies. Emerging approaches include self-amplifying RNA systems, tissue-specific design, and AI-driven optimisation that mimics natural selection to create more effective and biologically coherent treatments.

The discussion also reframes RNA’s so-called “fragility” as a functional feature, enabling therapies with controlled duration and predictable behaviour. Looking ahead, the field is shifting toward an evolution-informed model, where RNA is treated as a dynamic, environment-sensitive system rather than a static drug.

Overall, this perspective signals a major paradigm shift: the next generation of RNA medicines will be designed to align with biology’s inherent logic, unlocking safer, smarter, and more adaptable therapeutics.